Highlights
NASDAQ: MRTX       Mirati Therapeutics
Last Price Today's Change   Day's Range   Trading Volume
103.17   +2.44 (2.42%)  100.43 - 103.48  289,646

Overview

 
Avg Volume (4 weeks):902,995
4 Weeks Range:74.00 - 106.43
4 Weeks Price Volatility (%):
89.95%
52 Weeks Range:34.39 - 111.99
52 Weeks Price Volatility (%):
88.63%
Average Price Target:-

Headlines



No recent Headlines for this stock.


Business Background

Mirati Therapeutics is an American biotechnology company. The company’s medical focus is precision medicine: genetically targeted oncology therapeutics for selected patients. Mirati’s drug candidates target specific genetic and epigenetic drivers of cancer. Its portfolio includes MGCD265, MGCD516, and mocetinostat. MGCD265 and MGCD516 are orally bioavailable inhibitors with distinct target profiles aiming to treat patients with non-small cell lung cancer and other solid tumors. MGCD265 and MGCD516 are in clinical development. Mocetinostat is an orally bioavailable, Class 1 selective histone deacetylase inhibitor in clinical development in collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.

  Be the first to like this.
 


 

2999  2600  389  2989 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 FCEL 0.889+0.079 
 CHK 0.69-0.012 
 CSCO 44.91-3.55 
 AMD 38.35+0.83 
 CPE 4.19-0.27 
 AABA 19.630.00 
 NIO 1.75-0.15 
 NOK 3.37-0.10 
 SNNA 0.27+0.11 
 BAC 32.70-0.09 
Partners & Brokers